Patient response
| Relapsed/refractory patients, age, y/sex . | No. previous inductions . | Pretreatment karyotype . | Presenting WBC × 103/μL . | % BM blasts . | Response . |
|---|---|---|---|---|---|
| 75/M | 3 | 46,XY,dup(1)(q21q41)(2)/46,XY,del(3)(p21.1p21.3)(2)/46,XY(16) | 1.8 | 4 | |
| 66//F | 2 | 46,XX,del(5)(q22q33)(1)/55–56,sl,+1,+2,+8, del(8)(p11.2p23)x2,+9,+10,+11, del(12)(q13q15),+13,+14,+14,add(14)(q32),-17,add(18)(p11.2), add(19)(p13.2), +21,+22,del(22)(q13), +mar1, +mar2,+mar3,+mar4(cp8)/55–56,sdl1,add(4)(q32), -add(14)(q32)(cp5)/46,XX(5)/nonclonal(1) | 0.9 | 42 | |
| 67/M | 1 | Normal | 0.6 | 42 | CRi |
| 50/F | 2 | 46X,t(x;10;11),del(12p) | 22 | 86 | |
| 77/F | 2 | Unobtainable (dry tap) | 2.1 | 63 | |
| 32/M | 3 | 45,X,-Y,t(8;21)(q22;q22)cp7)/46,XY(13) | 1.6 | 18 | |
| 70/M | 3 | 94 < 4n >, XXYY,+13,+13(9)/46,XY(11) | 1.2 | 31 | |
| 73/M | 1 | Normal | 0.4 | 19 | CRi |
| 57/M | 4 | 47,XY,+8[16]/47,idem,t(2;12)(p16;q21)[1]/non-clonal abnormalities[3] | 6.8 | 81 |
| Relapsed/refractory patients, age, y/sex . | No. previous inductions . | Pretreatment karyotype . | Presenting WBC × 103/μL . | % BM blasts . | Response . |
|---|---|---|---|---|---|
| 75/M | 3 | 46,XY,dup(1)(q21q41)(2)/46,XY,del(3)(p21.1p21.3)(2)/46,XY(16) | 1.8 | 4 | |
| 66//F | 2 | 46,XX,del(5)(q22q33)(1)/55–56,sl,+1,+2,+8, del(8)(p11.2p23)x2,+9,+10,+11, del(12)(q13q15),+13,+14,+14,add(14)(q32),-17,add(18)(p11.2), add(19)(p13.2), +21,+22,del(22)(q13), +mar1, +mar2,+mar3,+mar4(cp8)/55–56,sdl1,add(4)(q32), -add(14)(q32)(cp5)/46,XX(5)/nonclonal(1) | 0.9 | 42 | |
| 67/M | 1 | Normal | 0.6 | 42 | CRi |
| 50/F | 2 | 46X,t(x;10;11),del(12p) | 22 | 86 | |
| 77/F | 2 | Unobtainable (dry tap) | 2.1 | 63 | |
| 32/M | 3 | 45,X,-Y,t(8;21)(q22;q22)cp7)/46,XY(13) | 1.6 | 18 | |
| 70/M | 3 | 94 < 4n >, XXYY,+13,+13(9)/46,XY(11) | 1.2 | 31 | |
| 73/M | 1 | Normal | 0.4 | 19 | CRi |
| 57/M | 4 | 47,XY,+8[16]/47,idem,t(2;12)(p16;q21)[1]/non-clonal abnormalities[3] | 6.8 | 81 |
WBC indicates white blood cell.